249 related articles for article (PubMed ID: 22540895)
1. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.
Frånlund M; Carlsson S; Stranne J; Aus G; Hugosson J
BJU Int; 2012 Sep; 110(5):638-43. PubMed ID: 22540895
[TBL] [Abstract][Full Text] [Related]
2. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
Hugosson J; Aus G; Bergdahl S; Fernlund P; Frösing R; Lodding P; Pihl CG; Lilja H
BJU Int; 2003 Dec; 92 Suppl 2():39-43. PubMed ID: 14983953
[TBL] [Abstract][Full Text] [Related]
3. Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective.
Kash DP; Lal M; Hashmi AH; Mubarak M
Asian Pac J Cancer Prev; 2014; 15(7):3087-91. PubMed ID: 24815452
[TBL] [Abstract][Full Text] [Related]
4. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
5. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
Collin SM; Metcalfe C; Donovan J; Lane JA; Davis M; Neal D; Hamdy F; Martin RM
BJU Int; 2008 Nov; 102(10):1400-6. PubMed ID: 18540932
[TBL] [Abstract][Full Text] [Related]
6. A retrospective comparison between transrectal and transperineal prostate biopsy in the detection of prostate cancer.
Di Franco CA; Jallous H; Porru D; Giliberto GL; Cebrelli T; Tinelli C; Rovereto B
Arch Ital Urol Androl; 2017 Mar; 89(1):55-59. PubMed ID: 28403597
[TBL] [Abstract][Full Text] [Related]
7. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
8. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
10. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
[TBL] [Abstract][Full Text] [Related]
11. Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Konaka H; Mizokami A; Namiki M
J Cancer Res Clin Oncol; 2014 Jan; 140(1):53-9. PubMed ID: 24165867
[TBL] [Abstract][Full Text] [Related]
12. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
Rowe EW; Laniado ME; Walker MM; Patel A
BJU Int; 2005 Jun; 95(9):1249-52. PubMed ID: 15892810
[TBL] [Abstract][Full Text] [Related]
14. Prediction of prostate cancer in extended-field biopsies of the prostate.
Winkler MH; Kulinskaya E; Gillatt DA
BJU Int; 2004 Mar; 93(4):516-21. PubMed ID: 15008721
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
Chun FK; Perrotte P; Briganti A; Benayoun S; Lebeau T; Ramirez A; Lewinshtein DJ; Valiquette L; Guay JP; Karakiewicz PI
BJU Int; 2006 Jul; 98(1):50-3. PubMed ID: 16831142
[TBL] [Abstract][Full Text] [Related]
16. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
[TBL] [Abstract][Full Text] [Related]
17. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
19. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
20. The influence of prostate volume on the prostate-specific antigen (PSA) level adjusted for the transition zone volume and free-to-total PSA ratio: a prospective study.
Moon DG; Yu JW; Lee JG; Kim JJ; Koh SK; Cheon J
BJU Int; 2000 Oct; 86(6):670-4. PubMed ID: 11069374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
